B+
Bull case
25%
Probability
Target price
$3.60
+17.6% vs current
GDRX
GoodRxANasdaq / Health Care Equipment & Services
Last Price
At close
2026-07-18
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$3.10
+1.3% vs current
B-
Bear case
25%
Probability
Target price
$2.20
-28.1% vs current
AI sentiment snapshot
Latest data as of 2026-07-01
Recent news sentiment (30D)
+30.0
Positive
Company
-
Unavailable
Macro
+30.0
Positive
Pulse
-
Unavailable
Sentiment proxy
+41.6
Score
AI commentary
Primary-source evidence quality is strong, but this is still a low-coverage monitoring name. Recent tone improved after the May 6, 2026 earnings release and raised outlook, and June news flow stayed active around product and channel expansion, yet the thesis still hinges on whether Pharma Direct and subscriptions can scale faster than the legacy prescription business declines. No usable social-context packet was provided, so conviction should come from upcoming operating proof points rather than narrative momentum.
RankAlpha Sentiment Codex - 2026-07-01
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-31eventNext results must confirm Pharma Direct can keep offsetting legacy prescription pressureHigh impact
Q1 showed Pharma Direct revenue up 82% year over year to $52.2 million and subscription revenue up 16%, but total revenue still fell 4% and prescription transactions revenue fell 24%; management also said lower unit economics are expected to continue in the near term, so the next print is the main proof point on whether the newer mix can sustainably outrun legacy declines [#SEC-8K-2026-05-06].
2026-09-30catalystCompanion launch can test whether subscriptions become a more durable recurring legHigh impact
GoodRx launched the $14.99-per-month GoodRx Companion membership on May 27, 2026, bundling free and low-cost generics, telehealth visits, and routine-care savings; management framed it as a broader subscription and recurring-revenue expansion, so early uptake matters for mix and retention [#IR-2026-05-27].
2026-12-31catalystEmployer Direct expands GoodRx into an enterprise access channel, but materiality is still unprovenHigh impact
GoodRx launched Employer Direct on February 24, 2026 to let employers subsidize discounted cash prices on high-impact brand drugs, including GLP-1s, without changing core plan design; management called it a potentially meaningful new growth opportunity, but investor confidence likely depends on additional employer adoption beyond the initial partner set [#IR-2026-02-24].
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-01 • Updated nightlySource: Internal modelMethodology